Man-Seong Park

List of Publications by Year in Descending Order

93 papers	2,396 citations	21 h-index	47 g-index
96 ext. papers	2,882 ext. citations	6 avg, IF	4.74 L-index

#	Paper	IF	Citations
93	COVID-19 Cluster Linked to Aerosol Transmission of SARS-CoV-2 via Floor Drains.. *Journal of Infectious Diseases*, **2022**,	7	1
92	Insights into the immune responses of SARS-CoV-2 in relation to COVID-19 vaccines.. *Journal of Microbiology*, **2022**, 60, 308-320	3	0
91	Viable SARS-CoV-2 Shedding Under Remdesivir and Dexamethasone Treatment.. *Journal of Infection*, **2022**,	18.9	0
90	Nosocomial Outbreak by Delta Variant From a Fully Vaccinated Patient.. *Journal of Korean Medical Science*, **2022**, 37, e133	4.7	2
89	Transmission and Infectious SARS-CoV-2 Shedding Kinetics in Vaccinated and Unvaccinated Individuals. *JAMA Network Open*, **2022**, 5, e2213606	10.4	10
88	MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants. *Frontiers in Immunology*, **2021**, 12, 778829	8.4	0
87	Dynamics of Viral Shedding and Symptoms in Patients with Asymptomatic or Mild COVID-19. *Viruses*, **2021**, 13,	6.2	2
86	Feasibility of ultraviolet light-emitting diode irradiation robot for terminal decontamination of coronavirus disease 2019 (COVID-19) patient rooms. *Infection Control and Hospital Epidemiology*, **2021**, 1-6	2	5
85	TRIM28 functions as a negative regulator of aggresome formation. *Autophagy*, **2021**, 1-17	10.2	1
84	Antiviral Efficacy of Pralatrexate against SARS-CoV-2. *Biomolecules and Therapeutics*, **2021**, 29, 268-272	4.2	1
83	The Immune Correlates of Vaccine. *Vaccines*, **2021**, 9,	5.3	1
82	Multifactorial Traits of SARS-CoV-2 Cell Entry Related to Diverse Host Proteases and Proteins. *Biomolecules and Therapeutics*, **2021**, 29, 249-262	4.2	0
81	Effective inactivated influenza vaccine for the elderly using a single-stranded RNA-based adjuvant. *Scientific Reports*, **2021**, 11, 11981	4.9	0
80	Risk of coronavirus disease 2019 transmission in an emergency department with multiple open beds. *Clinical Microbiology and Infection*, **2021**, 27, 1531-1533	9.5	
79	MERS-CoV and SARS-CoV-2 replication can be inhibited by targeting the interaction between the viral spike protein and the nucleocapsid protein. *Theranostics*, **2021**, 11, 3853-3867	12.1	8
78	Neutralizing Antibody Responses to SARS-CoV-2 in Korean Patients Who Have Recovered from COVID-19. *Yonsei Medical Journal*, **2021**, 62, 584-592	3	3
77	Frequent Occurrence of SARS-CoV-2 Transmission among Non-close Contacts Exposed to COVID-19 Patients. *Journal of Korean Medical Science*, **2021**, 36, e233	4.7	2

76	Nosocomial Outbreak of COVID-19 in a Hematologic Ward. *Infection and Chemotherapy*, **2021**, 53, 332-341	3.9	5
75	A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein. *Nature Communications*, **2021**, 12, 288	17.4	108
74	Duration of Culturable SARS-CoV-2 in Hospitalized Patients with Covid-19. *New England Journal of Medicine*, **2021**, 384, 671-673	59.2	90
73	Human infection with Seoul orthohantavirus in Korea, 2019. *PLoS Neglected Tropical Diseases*, **2021**, 15, e0009168	4.8	1
72	A high-resolution temporal atlas of the SARS-CoV-2 translatome and transcriptome. *Nature Communications*, **2021**, 12, 5120	17.4	10
71	Seroepidemiologic survey of emerging vector-borne infections in South Korean forest/field workers. *PLoS Neglected Tropical Diseases*, **2021**, 15, e0009687	4.8	
70	Diagnostic usefulness of subgenomic RNA detection of viable SARS-CoV-2 in patients with COVID-19. *Clinical Microbiology and Infection*, **2021**,	9.5	3
69	Clustering and multiple-spreading events of nosocomial severe acute respiratory syndrome coronavirus 2 infection. *Journal of Hospital Infection*, **2021**, 117, 28-36	6.9	6
68	Immunogenicity and safety of a modified three-dose priming and booster schedule for the Hantaan virus vaccine (Hantavax): A multi-center phase III clinical trial in healthy adults. *Vaccine*, **2020**, 38, 8016-8023	4.1	2
67	Animal models for the risk assessment of viral pandemic potential. *Laboratory Animal Research*, **2020**, 36, 11	1.9	3
66	Glycosylation generates an efficacious and immunogenic vaccine against H7N9 influenza virus. *PLoS Biology*, **2020**, 18, e3001024	9.7	4
65	Phylogeographic diversity and hybrid zone of Hantaan orthohantavirus collected in Gangwon Province, Republic of Korea. *PLoS Neglected Tropical Diseases*, **2020**, 14, e0008714	4.8	4
64	In Vitro Virucidal Effect of Povidone-Iodine Against SARS-CoV-2. *Journal of Bacteriology and Virology*, **2020**, 50, 195-202	0.3	1
63	Preclinical study of influenza bivalent vaccine delivered with a two compartmental microneedle array. *Journal of Controlled Release*, **2020**, 324, 280-288	11.7	15
62	Abdominal and Pelvic Organ Failure Induced by Intraperitoneal Influenza A Virus Infection in Mice. *Frontiers in Microbiology*, **2020**, 11, 1713	5.7	3
61	Genetic diversity and phylogeography of Jeju Orthohantavirus (Hantaviridae) in the Republic of Korea. *Virology*, **2020**, 543, 13-19	3.6	0
60	Novel Small Molecule Targeting the Hemagglutinin Stalk of Influenza Viruses. *Journal of Virology*, **2019**, 93,	6.6	11
59	Peritoneal Cells Mediate Immune Responses and Cross-Protection Against Influenza A Virus. *Frontiers in Immunology*, **2019**, 10, 1160	8.4	5

58	A Systems Vaccinology Approach Reveals the Mechanisms of Immunogenic Responses to Hantavax Vaccination in Humans. *Scientific Reports*, **2019**, 9, 4760	4.9	12
57	Production of a Monoclonal Antibody Targeting the M Protein of MERS-CoV for Detection of MERS-CoV Using a Synthetic Peptide Epitope Formulated with a CpG-DNA-Liposome Complex. *International Journal of Peptide Research and Therapeutics*, **2019**, 25, 819-826	2.1	6
56	Preparation of H1N1 microneedles by a low-temperature process without a stabilizer. *European Journal of Pharmaceutics and Biopharmaceutics*, **2019**, 143, 1-7	5.7	10
55	Evolutionary relationship analysis of Middle East respiratory syndrome coronavirus 4a and 4b protein coding sequences. *Journal of Veterinary Science*, **2019**, 20, e1	1.6	4
54	Generation and characterization of a monoclonal antibody against MERS-CoV targeting the spike protein using a synthetic peptide epitope-CpG-DNA-liposome complex. *BMB Reports*, **2019**, 52, 397-402	5.5	11
53	Contribution of Container Types on Cosmetics Contamination. *Annals of Dermatology*, **2019**, 31, 588-590	0.4	
52	Improving Pneumovirus Isolation Using a Centrifugation and AZD1480 Combined Method. *Journal of Microbiology and Biotechnology*, **2019**, 29, 2006-2013	3.3	0
51	Viral Fitness Landscapes in Diverse Host Species Reveal Multiple Evolutionary Lines for the NS1 Gene of Influenza A Viruses. *Cell Reports*, **2019**, 29, 3997-4009.e5	10.6	5
50	Distinct molecular evolution of influenza H3N2 strains in the 2016/17 season and its implications for vaccine effectiveness. *Molecular Phylogenetics and Evolution*, **2019**, 131, 29-34	4.1	3
49	One-step multiplex real-time RT-PCR for detection and typing of dengue virus. *Molecular and Cellular Probes*, **2019**, 43, 86-91	3.3	5
48	A Single Amino Acid in the Polymerase Acidic Protein Determines the Pathogenicity of Influenza B Viruses. *Journal of Virology*, **2018**, 92,	6.6	13
47	Effects of heat-killed Lactobacillus plantarum against influenza viruses in mice. *Journal of Microbiology*, **2018**, 56, 145-149	3	20
46	Effects of and Probiotics on Human Seasonal and Avian Influenza Viruses. *Journal of Microbiology and Biotechnology*, **2018**, 28, 893-901	3.3	19
45	Towards the Application of Human Defensins as Antivirals. *Biomolecules and Therapeutics*, **2018**, 26, 242-254	4.2	44
44	Development of a diagnostic system for detection of specific antibodies and antigens against Middle East respiratory syndrome coronavirus. *Microbiology and Immunology*, **2018**, 62, 574-584	2.7	8
43	Salinomycin Inhibits Influenza Virus Infection by Disrupting Endosomal Acidification and Viral Matrix Protein 2 Function. *Journal of Virology*, **2018**, 92,	6.6	33
42	Single PA mutation as a high yield determinant of avian influenza vaccines. *Scientific Reports*, **2017**, 7, 40675	4.9	5
41	Dynamic Circulation and Genetic Exchange of a Shrew-borne Hantavirus, Imjin virus, in the Republic of Korea. *Scientific Reports*, **2017**, 7, 44369	4.9	15

40	Evolutionary relationships of the hexon and penton base genes of novel squirrel adenovirus. *Molecular Phylogenetics and Evolution*, **2017**, 116, 25-29	4.1	3
39	Adaptive mutations of neuraminidase stalk truncation and deglycosylation confer enhanced pathogenicity of influenza A viruses. *Scientific Reports*, **2017**, 7, 10928	4.9	17
38	Phylogenetic relationships of the HA and NA genes between vaccine and seasonal influenza A(H3N2) strains in Korea. *PLoS ONE*, **2017**, 12, e0172059	3.7	6
37	Effects of HA and NA glycosylation pattern changes on the transmission of avian influenza A(H7N9) virus in guinea pigs. *Biochemical and Biophysical Research Communications*, **2016**, 479, 192-197	3.4	14
36	The recent ancestry of Middle East respiratory syndrome coronavirus in Korea has been shaped by recombination. *Scientific Reports*, **2016**, 6, 18825	4.9	25
35	Reassortment compatibility between PB1, PB2, and HA genes of the two influenza B virus lineages in mammalian cells. *Scientific Reports*, **2016**, 6, 27480	4.9	8
34	Viral shedding from diverse body fluids in a patient with severe fever with thrombocytopenia syndrome. *Journal of Clinical Virology*, **2016**, 80, 33-5	14.5	17
33	Genome-Wide Analysis of Human Metapneumovirus Evolution. *PLoS ONE*, **2016**, 11, e0152962	3.7	12
32	Original Antigenic Sin Response to RNA Viruses and Antiviral Immunity. *Immune Network*, **2016**, 16, 261-270	2.1	18
31	Genetic Diversity and Reassortment of Hantaan Virus Tripartite RNA Genomes in Nature, the Republic of Korea. *PLoS Neglected Tropical Diseases*, **2016**, 10, e0004650	4.8	24
30	Anti-influenza effect of Cordyceps militaris through immunomodulation in a DBA/2 mouse model. *Journal of Microbiology*, **2014**, 52, 696-701	3	21
29	Effects of a hemagglutinin D222G substitution on the pathogenicity of 2009 influenza A (H1N1) virus in mice. *Archives of Virology*, **2014**, 159, 2559-65	2.6	3
28	Combination effects of peramivir and favipiravir against oseltamivir-resistant 2009 pandemic influenza A(H1N1) infection in mice. *PLoS ONE*, **2014**, 9, e101325	3.7	14
27	Inhibition of Pseudomonas aeruginosa with a recombinant RNA-based viral vector expressing human β-defensin 4. *BMC Microbiology*, **2014**, 14, 237	4.5	7
26	The PDZ-binding motif of the avian NS1 protein affects transmission of the 2009 influenza A(H1N1) virus. *Biochemical and Biophysical Research Communications*, **2014**, 449, 19-25	3.4	7
25	Phylogenetic analysis of a swine influenza A(H3N2) virus isolated in Korea in 2012. *PLoS ONE*, **2014**, 9, e88782	3.7	7
24	Aronia melanocarpa and its components demonstrate antiviral activity against influenza viruses. *Biochemical and Biophysical Research Communications*, **2013**, 440, 14-9	3.4	47
23	DBA/2 mouse as an animal model for anti-influenza drug efficacy evaluation. *Journal of Microbiology*, **2013**, 51, 866-71	3	13

22	The anti-influenza virus effect of Phellinus igniarius extract. *Journal of Microbiology*, **2013**, 51, 676-81	3	28
21	Genetic requirement for hemagglutinin glycosylation and its implications for influenza A H1N1 virus evolution. *Journal of Virology*, **2013**, 87, 7539-49	6.6	40
20	Cell Culture-based Influenza Vaccines as Alternatives to Egg-based Vaccines. *Journal of Bacteriology and Virology*, **2013**, 43, 9	0.3	10
19	Susceptibility of human H3N2 influenza virus to oseltamivir in South Korea, 2009-2011. *Journal of Microbiology*, **2012**, 50, 1067-70	3	5
18	N-linked glycosylation in the hemagglutinin of influenza A viruses. *Yonsei Medical Journal*, **2012**, 53, 886-93	3	35
17	A Novel PA-X Protein Translated from Influenza A Virus Segment 3. *Journal of Bacteriology and Virology*, **2012**, 42, 368	0.3	1
16	An Universal Approach to Getting Ahead for Influenza B Vaccines. *Journal of Bacteriology and Virology*, **2012**, 42, 363	0.3	5
15	Antiviral Agents Against Influenza Viruses. *Journal of Bacteriology and Virology*, **2012**, 42, 284	0.3	11
14	GFP-expressing influenza A virus for evaluation of the efficacy of antiviral agents. *Journal of Microbiology*, **2012**, 50, 359-62	3	12
13	Immunization with a hemagglutinin-derived synthetic peptide formulated with a CpG-DNA-liposome complex induced protection against lethal influenza virus infection in mice. *PLoS ONE*, **2012**, 7, e48750	3.7	20
12	Surface glycoproteins determine the feature of the 2009 pandemic H1N1 virus. *BMB Reports*, **2012**, 45, 653-8	5.5	8
11	Ebolavirus VP35 suppresses IFN production from conventional but not plasmacytoid dendritic cells. *Immunology and Cell Biology*, **2011**, 89, 792-802	5	38
10	Comparison of innate immune responses to pathogenic and putative non-pathogenic hantaviruses in vitro. *Virus Research*, **2011**, 160, 367-73	6.4	19
9	Expression of transgenes from newcastle disease virus with a segmented genome. *Journal of Virology*, **2008**, 82, 2692-8	6.6	25
8	Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. *Cancer Research*, **2007**, 67, 8285-92	10.1	129
7	Influenza virus evades innate and adaptive immunity via the NS1 protein. *Journal of Virology*, **2006**, 80, 6295-304	6.6	230
6	Engineered viral vaccine constructs with dual specificity: avian influenza and Newcastle disease. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 8203-8	11.5	179
5	Induction of cellular immune responses to simian immunodeficiency virus gag by two recombinant negative-strand RNA virus vectors. *Journal of Virology*, **2004**, 78, 9366-75	6.6	33

4	Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer. *Cancer Research*, **2004**, 64, 3265-70	10.1	92
3	Newcastle disease virus (NDV)-based assay demonstrates interferon-antagonist activity for the NDV V protein and the Nipah virus V, W, and C proteins. *Journal of Virology*, **2003**, 77, 1501-11	6.6	311
2	Newcastle disease virus V protein is a determinant of host range restriction. *Journal of Virology*, **2003**, 77, 9522-32	6.6	183
1	Recombinant Newcastle disease virus as a vaccine vector. *Journal of Virology*, **2001**, 75, 11868-73	6.6	196